In translational research described, we investigated biomarker expression by flow cytometry for MDM2 antagonist clinical response association in relapsed/refractory AML patients treated with idasanutlin-based therapy (Clinicaltrials.gov identifier: NCT01773408).
Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts / Reis, Bernhard; Jukofsky, Lori; Chen, Gong; Martinelli, Giovanni; Zhong, Hua; Venus So, W.; Dickinson, Michael J.; Drummond, Mark; Assouline, Sarit; Hashemyan, Maneja; Theron, Michel; Blotner, Steven; Lee, Je-Hwan; Kasner, Margaret; Yoon, Sung-Soo; Rueger, Ruediger; Seiter, Karen; Middleton, Steven A.; Kelly, Kevin R.; Vey, Norbert; Yee, Karen; Nichols, Gwen; Chen, Lin-Chi; Pierceall, William E. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - 101:5(2016), pp. e185-e188. [10.3324/haematol.2015.139717]
Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
MARTINELLI, GIOVANNI;
2016
Abstract
In translational research described, we investigated biomarker expression by flow cytometry for MDM2 antagonist clinical response association in relapsed/refractory AML patients treated with idasanutlin-based therapy (Clinicaltrials.gov identifier: NCT01773408).| File | Dimensione | Formato | |
|---|---|---|---|
|
101e185.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
633.06 kB
Formato
Adobe PDF
|
633.06 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
